Agilect Could Launch In Mid-2005 After Teva Responds To “Approvable” Letter
This article was originally published in The Pink Sheet Daily
Executive Summary
Written response will trigger FDA’s six-month review clock, setting an estimated action date in May. Teva and Eisai plan to launch the Parkinson’s disease therapy within two months following approval.
You may also be interested in...
FDA Extends Agilect User Fee Deadline Due To “Technical Error”
FDA is extending the user fee deadline for Teva's Parkinson's disease agent Agilect (rasagiline) by three months following the firm's submission of additional data to clarify a "technical error.
FDA Extends Agilect User Fee Deadline Due To “Technical Error”
FDA is extending the user fee deadline for Teva's Parkinson's disease agent Agilect (rasagiline) by three months following the firm's submission of additional data to clarify a "technical error.
Valeant Responds To Zelapar “Approvable” Letter For Parkinson’s
The “complete response” contains two safety studies per FDA’s request. Safety concerns for the fast-dissolving oral selegiline include drug interactions, hypertension due to “cheese effect.” Valeant plans a mid-2005 launch for the MAO-B inhibitor.